ArticleOncogene2018
hMENA isoforms impact NSCLC patient outcome through fibronectin/β1 integrin axis.
Open access · hybridAbstract read
In one paragraph
Article in Oncogene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Reciprocal regulation of hMENA and TGF-β signaling in cancer-associated fibroblasts promotes EMT, immunosuppression, poor prognosis, and ICT resistance in NSCLC.Journal for immunotherapy of cancer · 2026Article
- Cancer Organoids as reliable disease models to drive clinical development of novel therapies.Journal of experimental & clinical cancer research : CR · 2024Article
- Upregulation of ENAH by a PI3K/AKT/β-catenin cascade promotes oral cancer cell migration and growth via an ITGB5/Src axis.Cellular & molecular biology letters · 2024Article
- Transcription factors in fibroblast plasticity and CAF heterogeneity.Journal of experimental & clinical cancer research : CR · 2023Review
- hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.Journal for immunotherapy of cancer · 2023Article
- Spatially Resolved Proteomic and Transcriptomic Profiling of Anaplastic Lymphoma Kinase-Rearranged Pulmonary Adenocarcinomas Reveals Key Players in Inter- and Intratumoral Heterogeneity.International journal of molecular sciences · 2023Article
- Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11-13 2019, Verona, Italy.Cancer immunology, immunotherapy : CII · 2022Article
- Expression of the phagocytic receptors αFrontiers in immunology · 2022Article
- Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?Biology · 2021Review
- Fibronectin as a multiregulatory molecule crucial in tumor matrisome: from structural and functional features to clinical practice in oncology.Journal of experimental & clinical cancer research : CR · 2021Review
- Actin Cytoskeleton and Regulation of TGFβ Signaling: Exploring Their Links.Biomolecules · 2021Review
- LC-MS/MS-Based Quantitative Proteomics Analysis of Different Stages of Non-Small-Cell Lung Cancer.BioMed research international · 2021Article
- The actin modulator hMENA regulates GAS6-AXL axis and pro-tumor cancer/stromal cell cooperation.EMBO reports · 2020Article
- Fibronectin in Cancer: Friend or Foe.Cells · 2019Review
- 3D models in the new era of immune oncology: focus on T cells, CAF and ECM.Journal of experimental & clinical cancer research : CR · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 3 countries.
Francesca Di ModugnoTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Sheila SpadaTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Belinda PalermoTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Paolo ViscaLaboratory of Pathology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Pierluigi IapiccaTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Anna Di CarloTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Barbara AntonianiLaboratory of Pathology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Isabella SperdutiBiostatistics-Scientific Direction, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Anna Di BenedettoLaboratory of Pathology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Irene TerrenatoBiostatistics-Scientific Direction, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Marcella MottoleseLaboratory of Pathology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Francesco GandolfiDepartment of Physics, University Sapienza, Rome, Italy.
Francesco FaccioloThoracic Surgery Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Emily I ChenDepartment of Pharmacology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
Martin A SchwartzYale Cardiovascular Research Center, Departments of Internal Medicine, Cell Biology and Biomedical Engineering, Yale School of Medicine, New Haven, CT, 06511, USA.ORCID http://orcid.org/0000-0002-2071-1243
Angela SantoniDepartment of Molecular Medicine, University Sapienza, Rome, Italy.
Mina J BissellLife Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, 94720, USA.ORCID http://orcid.org/0000-0001-5841-4423
Paola NisticòTumor Immunology and Immunotherapy Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy. paola.nistico@ifo.gov.it.
Istituti di Ricovero e Cura a Carattere Scientifico · ITSapienza University of Rome · ITColumbia University Irving Medical Center · USLawrence Berkeley National Laboratory · USNational Cancer Institute · MYYale University · US
Funding
TRANS-NETWORK PROJECTSU54CA143836 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIPHARDT, JAN T. · 2009 to 2014
$15.1MThe Rho Family GTPases in Integrin SignalingR01GM047214 · NIGMS · YALE UNIVERSITY · PI SCHWARTZ, MARTIN A · 1991 to 2020
$6.3MDefinition of the Microenvironment in Breast CancerR01CA064786 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI BISSELL, MINA · 1995 to 2020
$6.1MDefinition of Microenvironment in Breast CancerR37CA064786 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI BISSELL, MINA · 2009 to 2013
$2.0MNCI NIH HHS R01 CA064786NCI NIH HHS R37 CA064786NCI NIH HHS U54 CA143836NIGMS NIH HHS R01 GM047214
Abstract
We demonstrated previously that the splicing of the actin regulator, hMENA, generates two alternatively expressed isoforms, hMENA
Indexed as
Carcinoma, Non-Small-Cell LungExtracellular MatrixFibronectinsGene Expression Regulation, NeoplasticHumansIntegrin beta1Lung NeoplasmsMicrofilament ProteinsProtein IsoformsSignal TransductionTumor MicroenvironmentEnah protein, humanFibronectinsIntegrin beta1Microfilament ProteinsProtein Isoforms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.